Peptide evidence grading

Short answer

This is a method note, not a therapy: a five-tier evidence scale running from human randomized trials down to anecdote, combined with a regulatory tier running from FDA-approved to prohibited. Applied to mid-2026 examples, most gray-market peptides land at Tier 3-4, meaning animal or mechanistic data only, while their regulatory status shifted with the April 2026 Category 2 removal and the July 2026 PCAC reviews. It is a proposed framework for sorting claims, not a clinical tool.

Summary drafted from this entry’s sources; editorial review pending.

01Key questions

How does the framework grade peptide evidence?

Five tiers: Tier 1 is human RCTs or meta-analyses, Tier 2 human observational studies, Tier 3 animal studies, Tier 4 in-vitro or mechanistic work, Tier 5 anecdote and marketing. A separate regulatory tier runs from FDA-approved to prohibited; the two combine into a composite risk score.

Where do popular peptides land on the scale?

As graded in mid-2026: BPC-157 and TB-500 at Tier 3 (mostly animal), Epitalon and GHK-Cu at Tier 3-4, and rapamycin at Tier 2 (human observational plus off-label use). Most popular peptides sit at animal or mechanistic level.

What is the peptide regulatory status in 2026?

Fluid. FDA removed 12 peptides from Category 2 in April 2026, and the July 23-24 PCAC meeting reviewed seven peptides for 503A Bulks List eligibility: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon. Outcomes were pending at the time of writing.

02Rationale

Peter Attia’s AMA #83 (April 2026) introduced numerical evidence grades for peptides (e.g., BPC-157: 9/10). Combined with the April 2026 FDA reclassification of 12 peptides from Category 2 (removing "significant safety concerns" designation) and the July 23-24, 2026 PCAC review of seven peptides for 503A Bulks List eligibility, there is clear market demand for a standardized, rigorous evidence grading framework that integrates both scientific evidence and regulatory status.

03Proposed Framework

Evidence Tiers (Scientific)

Tier 1: Human RCT or systematic review/meta-analysis (highest quality human data)
Tier 2: Human observational studies, cohort, case-control
Tier 3: Animal (in vivo) studies
Tier 4: In-vitro or mechanistic studies
Tier 5: Anecdote, marketing claims, or expert opinion only

Regulatory Tiers (2026 Status)

FDA-approved: Approved drug product
Compounding-available (Category 1 post-review): Eligible for 503A compounding if added to Bulks List
Restricted/Gray-market (Category 2 removed; under PCAC review): Previously restricted; now under formal evaluation (e.g., BPC-157, TB-500, Epitalon as of July 2026)
Prohibited: Category 2 with safety concerns upheld or withdrawn nominations not advancing

Composite Risk Profile

Evidence tier + Regulatory tier = Operator risk score (for telehealth/clinic protocol design and investor diligence).

04Applied Examples (Updated with 2026 Regulatory Context)

BPC-157: Evidence Tier 3 (primarily animal + limited human); Regulatory: Category 2 removed April 2026 → PCAC review July 23, 2026 (ulcerative colitis indication). Composite: Moderate-high risk pending PCAC outcome.
2026 PCAC Meeting (July 23-24): FDA Pharmacy Compounding Advisory Committee reviewed 7 peptides for 503A Bulks List eligibility:
July 23: BPC-157 (UC), KPV, TB-500, MOTS-C (obesity/osteoporosis)
July 24: Emideltide/DSIP (opioid withdrawal), Semax (ischemia/migraine), Epitalon (insomnia) Outcomes pending as of July 25, 2026; no final Bulks List additions announced. Human evidence flagged as limited/scant for most (small/uncontrolled studies); safety signals noted (e.g., Epitalon telomerase/carcinogenicity concerns, Semax anticoagulant effects). FDA Peptide Reclassification 2026 — Regulatory Intelligence
Rapamycin: Evidence Tier 2 (human observational + off-label use); Regulatory: Off-label (not bulk compounding restricted).
Epitalon: Evidence Tier 3-4 (animal/mechanistic, Russian bioregulator data); Regulatory: PCAC review July 24, 2026 (insomnia).
GHK-Cu: Evidence Tier 3-4; Regulatory: Removed from Category 1 April 2026; follow-up PCAC before Feb 2027.
TB-500 / Thymosin Beta-4: Evidence Tier 3 (animal wound healing); Regulatory: PCAC July 23, 2026.

Human vs Animal vs In-Vitro Separation Required in all applications: Prioritize Tier 1-2 human data; flag Tier 3+ for additional disclaimers.

05Use Cases

Telehealth protocol design and patient selection
Clinic patient education materials
Content creation and claims substantiation
Investor due diligence on compounding/telehealth valuations
Post-PCAC scenario planning (July 2026 outcomes)

06Personalization Angles

Peter Attia / The Drive (evidence grading)
Gary Brecka / 10X Health
Andrew Huberman (mechanism focus)
Nava Health, Ways2Well, HealingMaps (practitioners)
Integration with 01 - Peptides/FDA Peptide Reclassification 2026 — Regulatory Intelligence